glp-1 obesity drug news today 2025 As drugs continue to gain popularity for weight loss, a lesser-known side effect is drawing attention from podiatrists: “Ozempic feet.” Story🔗below Obesity GLP-1 Market Size to
Description
Semaglutide works in a similar way by helping to slow down how quickly food leaves the stomach and by acting on areas of the brain involved in appetite control
Do not reuse
A new case report highlights the potential risk of "anhedonia" from high doses of tirzepatide, though it can be treated effectively.
Carey MD Krieger School of Arts and Sciences, Johns Hopkins University, Baltimore
Amgens MariTide leads the GLP-1 obesity therapy market in 2025 with innovative design, Phase-3 trials, and strong potential for effective weight loss.
Across large employers that cover the drugs for weight loss, many require participation in lifestyle or nutrition programs before coverage applies
